April 2016 marks the beginning of a new phase of the Graphene Flagship1. This first phase of the Core Project — lasting for 3 years and supported by Horizon 2020, the EU Framework Programme for Research and Innovation . com/CNOjo6) — consolidates some of the topics already explored during the ramp-up phase of this €1 billion research initiative, and further extends the technological and scientific remit by launching Work Packages focused on new applications (http:// go.nature.com/CQ1nIM). Among them, a new Biomedical Technologies Work Package will investigate whether 2D materials can be leveraged for the development of diagnostic or therapeutic tools for healthcare. In keeping with the spirit of the Flagship, fundamental research in this area will need to attract the interest of industrial partners, who will have to provide part of the financial support for technological development, as well as assist with the clinical translation of the research output. Promoting these collaborations was the aim of a two-day Graphene Connect workshop ) held in February at the MINATEC centre, Grenoble, where scientists discussed with industry representatives how graphene might provide specific advantages for use in biomedical applications. During his introductory talk, Kostas Kostarelos (University of Manchester, UK) — who leads this new Work Package together with Jose Garrido (Catalan Institute of Nanoscience and Nanotechnology, Barcelona, Spain) — articulated in very simple terms the first question that must be considered: “why graphene?” Indeed, although graphene possesses certain properties that are desirable for several high-tech applications, what technological requirements this and other 2D materials could address in biomedicine requires further investigation. Implantable electronic devices — such as artificial retina implants or the bioelectronics interfaces envisioned by GlaxoSmithKline (a partner of the new Work Package) to treat diseases using electrical stimuli2 — must fulfil strict performance requirements to reduce patient discomfort. For instance, they must be small, flexible, stable in physiological conditions and able to provide reliable electrical performance for years. Although graphene possesses the structural and mechanical properties required by these devices, its stability and reliable operation in situ is less certain and will depend heavily on the quality and chemical reactivity of the specific materials used. Whether graphenebased interfaces can deliver electrical signals intense enough to stimulate the human nervous system, or outperform the sensors currently used to detect neuronal electrical activity, are also open questions that several groups, including that of Garrido, are trying to answer. The application of graphene to assist drug delivery is another area of potential significance. Many drugs with beneficial therapeutic properties can also present detrimental side effects, limiting their clinical application. The use of nanomaterials to immobilize and deliver these drugs can assist with preventing undesirable effects. Also, complementary studies are exploring strategies to controllably release the immobilized drugs when the appropriate biological target is identified. The ease by which graphene can be chemically modified seemingly lends itself well to such immobilization and delivery applications3. What will likely be a much more significant hurdle is the requirement that any graphene-based drug delivery system should present a watertight demonstration of its biocompatibility. It is not appropriate to make general statements on the behaviour of graphene, graphene oxide and other 2D materials when interacting with complex biological systems. Rather, specific properties such as flake size, defect density and surface chemistry dictate whether graphene is biologically inert or able to maintain therapeutic effectiveness without any kind of undesirable toxicity4. In future, it will therefore be particularly important to qualify any claims of graphene biocompatibility to account for these kinds of material characteristics. Only through this kind of detailed assessment can an optimal biological profile be achieved. Graphene has been touted as the next big thing in several industries other than biomedicine, from energy generation and storage to optoelectronics and structural materials. However, investor enthusiasm may be tempered by the long commercialization times and high development costs that material-based innovations have historically experienced. As explained in the Commentary on page 487 of this issue by Elicia Maine and Purnesh Seegopaul (Simon Fraser University, Vancouver, Canada), the success of a new material in improving the performance of an end product also depends on the complementary adaptation of manufacturing processes or device designs, which unavoidably requires additional time for its industrial adoption. To avoid discouraging investors’ interest, venture companies developing advanced materials should identify the most valuable commercial applications at an early stage and steer efforts in materials and manufacturing development accordingly. Whether or not new diagnostic and therapeutic devices will be one of the graphene applications to be prioritized is an interesting question that both the Graphene Flagship and researchers worldwide are now trying to explore. The next few years will tell us how far graphene’s steps into biomedicine can go. ❐
PLACE YOUR ADVERT HERE
- ACCOUNTING PROJECT TOPICS AND MATERIALS3553
- EDUCATION PROJECT TOPICS AND MATERIALS3486
- ENGLISH AND LINGUISTIC PROJECT TOPICS AND MATERIALS2939
- COMPUTER SCIENCE PROJECT TOPICS AND MATERIALS FINAL YEAR1274
- BANKING AND FINANCE PROJECT TOPICS AND MATERIALS1250
- BUSINESS ADMINISTRATION PROJECT TOPICS AND MATERIALS1236
- EDUCATION FOUNDATION GUIDANCE AND COUNSELLING TOPICS AND MATERIALS1045
- ZOOLOGY PROJECT TOPICS AND MATERIALS1002
- MASS COMMUNICATION PROJECT TOPICS AND MATERIALS1001
- ANIMAL SCIENCE PROJECT TOPICS AND MATERIALS978
- LAW PROJECT TOPICS AND MATERIALS896
- ARTS EDUCATION PROJECT TOPICS AND MATERIALS844
- MARKETING PROJECT TOPICS AND MATERIALS690
- AGRICULTURAL EXTENSION PROJECT TOPICS AND MATERIALS676
- PUBLIC ADMINISTRATION PROJECT TOPICS AND MATERIALS654
LATEST PROJECTS
STUDIES ON SOME ASPECTS OF ANTHRACNOSE-BLIGHT-DIEBACK COMPLEX OF CULTIVARS OF GRAPEVINES (VITIS SPP.) IN...
GENETIC VARIABILITY STUDIES OF TWENTY POTATO GENOTYPES
RELATIONSHIP OF HAEMOGLOBIN AND POTASSIUM POLYMORPHISM WITH CONFORMATION, MILK PRODUCTION AND BLOOD BIOCHEMICAL PROFILES...
ADOPTION OF AGRICULTURAL INNOVATIONS AMONG MEMBERS AND NON-MEMBERS OF WOMEN CO-OPERATIVE SOCIETIES IN OJU...
SMALL FARMER CREDIT WITH PARTICULAR REFERENCE TO NIGERIA
DISCLAIMER
All undertaking works, records and reports posted on this website, modishproject.com are the property/copyright of their individual proprietors. They are for research reference/direction purposes and the works are publicly supported. Do not present another person’s work as your own to maintain a strategic distance from counterfeiting its results. Use it as a guide and not to duplicate the work in exactly the same words (verbatim). modishproject.com is a vault of exploration works simply like academia.edu, researchgate.net, scribd.com, docsity.com, coursehero and numerous different stages where clients transfer works. The paid membership on modishproject.com is a method by which the site is kept up to help Open Education. In the event that you see your work posted here, and you need it to be eliminated/credited, it would be ideal if you call us on +2348053692035 or send us a mail along with the web address linked to the work, to [email protected]. We will answer to and honor each solicitation. Kindly note notification it might take up to 24 - 48 hours to handle your solicitation.